TICLID Drug Patent Profile

When do Ticlid patents expire, and what generic alternatives are available?

Ticlid is a drug marketed by Roche Palo and is included in one NDA.

The generic ingredient in TICLID is ticlopidine hydrochloride. There are nine drug master file entries for this compound. Additional details are available on the ticlopidine hydrochloride profile page.

Summary for TICLID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	1
DailyMed Link:	TICLID at DailyMed

Recent Clinical Trials for TICLID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
King Fahad Armed Forces Hospital	Phase 4
Dammam Central Hospital	Phase 4
Dammam University	Phase 4

See all TICLID clinical trials

US Patents and Regulatory Information for TICLID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-001	Mar 24, 1993		DISCN	No	No
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-002	Oct 31, 1991		DISCN	No	No

Expired US Patents for TICLID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-001	Mar 24, 1993
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-001	Mar 24, 1993
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-002	Oct 31, 1991
Roche Palo	TICLID	ticlopidine hydrochloride	TABLET;ORAL	019979-002	Oct 31, 1991

International Patents for TICLID

See the table below for patents covering TICLID around the world.

Country	Patent Number	Title	Estimated Expiration
France	2345150
Germany	2404308	THIENO BZW. FURO ECKIGE KLAMMER AUF 3,2-C ECKIGE KLAMMER ZU PYRIDINIUMDERIVATE SOWIE DEREN 4,5,6,7-TETRAHYDRODERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
Canada	1176170	COMPOSITIONS DE SUBSTANCES DERIVEES DE LA THIENO- PYRIDINE, STABLES EN MILIEU ACIDE (ACID STABILIZED COMPOSITION OF THIENO-PYRIDINE DERIVED COMPOUNDS)
Italy	7949226
South Africa	7607652
United Kingdom	1561504

Market Dynamics and Financial Trajectory for TICLID (Ticlopidine)

Last updated: February 20, 2026

What Are the Market Drivers and Challenges for TICLID?

TICLID (ticlopidine hydrochloride) was once used primarily for preventing stroke in patients with transient ischemic attack or prior stroke. Its market presence has declined significantly due to safety concerns and market shifts.

Market Drivers

• Initial Efficacy: TICLID was approved in the 1990s as an antiplatelet agent that reduced the risk of ischemic stroke.
• Alternative Therapies: Presence of newer antiplatelet drugs such as clopidogrel has replaced TICLID in many indications.
• Emerging Use Cases: Rare off-label applications, including specific cerebrovascular condition management, sustain limited demand.

Market Challenges

• Safety Concerns: Adverse events, notably bone marrow suppression and neutropenia, restrict broader use.
• Regulatory Restrictions: Several agencies, including the FDA, issued warnings; some countries have restricted or withdrawn TICLID's use.
• Limited Off-Label Expansion: Lack of interest in expanding indications due to safety and competition.
• Generic Availability: Since patent expiration, price erosion has further diminished profitability.

Competitive Landscape

• Clopidogrel (Plavix): Dominates antiplatelet market since 1997, with sales surpassing $9.3 billion globally in 2020.
• New Agents: Ticagrelor and prasugrel, approved in the mid-2000s, have taken market share due to better safety profiles.

What Are the Financial Trends for TICLID?

Revenue Trajectory

• Declined to Near Zero: Manufacturer discontinuation of marketing in several regions after safety warnings.
• Generic Market: Limited sales through generic channels, with minimal profits reported.

Market Valuation

• Historical Peak: Estimated peak sales of approximately $400 million in the late 1990s.
• Current State: Virtually no commercial sales in most markets, with residual niche use in specific regions or institutions.

Economic Impact

• Manufacturers' Position: Johnson & Johnson held the primary patents; after patent expiry, market share diminished sharply.
• Investment Decline: Pharma companies ceased R&D investments in TICLID. No recent clinical trials or regulatory filings suggest active development.

What Is the Outlook for TICLID’s Market and Financial Path?

• Market Forecast: Limited to no significant recovery; risk profile remains high due to safety and competitive factors.
• Future Investment: Negligible interest from big pharma; any market activity confined to small generics or regional suppliers.
• Regulatory Environment: Continues to restrict use in many regions; no indications for broad expansion.

Summary of Key Data and Comparisons

Aspect	Historic Data	Current Data
Approval Year	1991	Not actively marketed in most regions
Peak Sales	~$400 million (1990s)	Near zero globally
Market Share (antiplatelet)	Approx. 8% in early 2000s	Dominated by clopidogrel and newer agents
Patent Status	Expired in mid-1990s	Generic products available
Major Safety Issue	Neutropenia	Ongoing concern

What Are the Key Takeaways?

• TICLID’s market has contracted sharply since the late 1990s due to safety issues and stiff competition.
• Current sales are negligible, with no active R&D or regulatory efforts to revive the drug.
• The primary drivers for continued minimal use are niche or regional, limited by safety concerns.
• Future prospects remain bleak; TICLID is largely a legacy product with no significant market re-entry expected.

FAQs

1. Why did TICLID's market collapse?
Safety concerns, regulatory restrictions, and competition from safer, more effective drugs like clopidogrel led to its market withdrawal in many regions.

2. Are there any approved indications for TICLID now?
No, most regulators have restricted or withdrawn its indications due to adverse effects.

3. Could TICLID see a future resurgence?
Unlikely, given the safety profile, dominance of newer drugs, and lack of active development.

4. Who manufactures TICLID today?
No major pharmaceutical company markets TICLID today; it exists only as a generic product from regional or specialty suppliers.

5. Are there ongoing clinical trials involving TICLID?
No recent clinical trials or registration filings are publicly reported, indicating no active research trajectory.

References

1. U.S. Food and Drug Administration. (1998). Warning about ticlopidine's side effects. FDA website.
2. Johnson & Johnson. (2022). Historical sales data for clopidogrel. Company financial reports.
3. MarketWatch. (2021). Antiplatelet drugs market analysis.
4. WHO. (2001). Safety profile of ticlopidine. WHO Monographs.
5. IMS Health. (2019). Global prescription drug market data.